Payment overview · 2025
General Payments
$1,030.01
35 reported records · 11 companies
Healthcare provider profile · identity verified
Jamil Abouelhossen, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FAJARDO, PR · NPI 1356347538
Verified facts
What the public records show
CMS Open Payments records show Jamil Abouelhossen, MD received $1,030.01 in general payments during 2025 across 35 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 18.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Kerendia, Lokelma, Mounjaro, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 243 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Bayer Puerto Rico Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 784 records involving 303 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 268 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Synjardy by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 210 claims for Eliquis by this doctor in 2024.
Eli Lilly Export S.A. Puerto Rico Branch reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 342 records involving 186 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 268 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 191 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $186.64 | 18.1% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $184.50 | 17.9% | 7 | 2025 |
| Eli Lilly Export S.A. Puerto Rico Branch | Unresolved — no canonical attribution shown | $150.00 | 14.6% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $141.76 | 13.8% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $124.99 | 12.1% | 1 | 2025 |
| Bayer Puerto Rico Inc. | Unresolved — no canonical attribution shown | $117.22 | 11.4% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $25.63 | 2.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.00 | 2.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $25.00 | 2.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $25.00 | 2.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.27 | 2.4% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,030.01 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc., Bayer Puerto Rico Inc. | $242.21 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $210.91 | 6 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $184.50 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Eli Lilly Export S.A. Puerto Rico Branch | $150.00 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Eli Lilly Export S.A. Puerto Rico Branch | $150.00 | 6 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $91.76 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $59.50 | 6 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $36.02 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $25.63 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $25.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 210 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 268 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 72 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 65 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
243 | 45 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Bayer Puerto Rico Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 784 supporting records · 303 recipient NPIs · example record 1225435793 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
268 | 46 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
182 | 49 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
210 | 40 |
| Eli Lilly Export S.A. Puerto Rico Branch Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 342 supporting records · 186 recipient NPIs · example record 1186464879 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
72 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
268 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
72 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
191 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1632 | 360 |
| Gabapentin | Gabapentin | 1360 | 263 |
| Losartan Potassium | Losartan Potassium | 1098 | 233 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 984 | 219 |
| Metformin Hcl | Metformin Hcl | 925 | 181 |
| Famotidine | Famotidine | 832 | 167 |
| Synthroid | Levothyroxine Sodium | 750 | 165 |
| Amlodipine Besylate | Amlodipine Besylate | 749 | 164 |
| Doxazosin Mesylate | Doxazosin Mesylate | 698 | 129 |
| Simvastatin | Simvastatin | 604 | 138 |
| Pantoprazole Sodium | Pantoprazole Sodium | 548 | 119 |
| Ezetimibe | Ezetimibe | 461 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 450 | 100 |
| Omeprazole | Omeprazole | 424 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 411 | 85 |
| Metoprolol Tartrate | Metoprolol Tartrate | 411 | 97 |
| Tamsulosin Hcl | Tamsulosin Hcl | 407 | 96 |
| Pioglitazone Hcl | Pioglitazone Hcl | 405 | 76 |
| Alendronate Sodium | Alendronate Sodium | 404 | 87 |
| Valsartan | Valsartan | 380 | 78 |
| Lisinopril | Lisinopril | 374 | 69 |
| Clopidogrel | Clopidogrel Bisulfate | 369 | 79 |
| Allopurinol | Allopurinol | 354 | 87 |
| Temazepam | Temazepam | 347 | 70 |
| Clonazepam | Clonazepam | 310 | 50 |
| Fenofibrate | Fenofibrate | 280 | 90 |
| Jardiance | Empagliflozin | 268 | 46 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 264 | 54 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 259 | 46 |
| Montelukast Sodium | Montelukast Sodium | 256 | 56 |
| Farxiga | Dapagliflozin Propanediol | 243 | 45 |
| Irbesartan | Irbesartan | 237 | 47 |
| Candesartan Cilexetil | Candesartan Cilexetil | 228 | 51 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 218 | 49 |
| Diclofenac Sodium | Diclofenac Sodium | 212 | 88 |
| Eliquis | Apixaban | 210 | 40 |
| Xarelto | Rivaroxaban | 202 | 48 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 196 | 47 |
| Trulicity | Dulaglutide | 191 | 26 |
| Carvedilol | Carvedilol | 184 | 40 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 182 | 60 |
| Synjardy | Empagliflozin/Metformin Hcl | 182 | 49 |
| Raloxifene Hcl | Raloxifene Hcl | 177 | 37 |
| Finasteride | Finasteride | 162 | 41 |
| Meclizine Hcl | Meclizine Hcl | 150 | 54 |
| Pregabalin | Pregabalin | 150 | 37 |
| Furosemide | Furosemide | 146 | 33 |
| Linzess | Linaclotide | 146 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 143 | 37 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 137 | 23 |
| Etodolac Er | Etodolac | 132 | 81 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 131 | 26 |
| Atenolol | Atenolol | 126 | 19 |
| Bumetanide | Bumetanide | 124 | 36 |
| Buspirone Hcl | Buspirone Hcl | 121 | 32 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 120 | 28 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 117 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 114 | 26 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 114 | 32 |
| Enalapril Maleate | Enalapril Maleate | 113 | 24 |
| Rivastigmine | Rivastigmine | 112 | 32 |
| Entresto | Sacubitril/Valsartan | 111 | 20 |
| Pentoxifylline | Pentoxifylline | 105 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 19 |
| Glyxambi | Empagliflozin/Linagliptin | 93 | 21 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 90 | 20 |
| Methotrexate | Methotrexate Sodium | 89 | 17 |
| Baclofen | Baclofen | 86 | 39 |
| Sertraline Hcl | Sertraline Hcl | 83 | 19 |
| Tradjenta | Linagliptin | 83 | 24 |
| Januvia | Sitagliptin Phosphate | 82 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 81 | 20 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 81 | 13 |
| Diclofenac Potassium | Diclofenac Potassium | 79 | 31 |
| Spironolactone | Spironolactone | 79 | 22 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 77 | 13 |
| Sucralfate | Sucralfate | 76 | 23 |
| Donepezil Hcl | Donepezil Hcl | 75 | 21 |
| Glipizide | Glipizide | 73 | 17 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 73 | 22 |
| Mounjaro | Tirzepatide | 72 | 17 |
| Ibuprofen | Ibuprofen | 71 | 22 |
| Memantine Hcl | Memantine Hcl | 70 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 70 | 22 |
| Glimepiride | Glimepiride | 69 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 67 | 19 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 67 | suppressed |
| Ozempic | Semaglutide | 65 | suppressed |
| Folic Acid | Folic Acid | 63 | 13 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 62 | 11 |
| Nifedipine Er | Nifedipine | 62 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 16 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 57 | 17 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 57 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 14 |
| Diclofenac Sodium Er | Diclofenac Sodium | 54 | 16 |
| Diltiazem Hcl | Diltiazem Hcl | 54 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 15 |
| Nabumetone | Nabumetone | 53 | 18 |
| Humalog | Insulin Lispro | 45 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 44 | suppressed |
| Cilostazol | Cilostazol | 44 | suppressed |
| Ramipril | Ramipril | 44 | suppressed |
| Verapamil Er | Verapamil Hcl | 44 | suppressed |
| Azithromycin | Azithromycin | 43 | 37 |
| Prednisone | Prednisone | 42 | 16 |
| Brilinta | Ticagrelor | 40 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 40 | 28 |
| Amiodarone Hcl | Amiodarone Hcl | 38 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | suppressed |
| Etodolac | Etodolac | 37 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Estazolam | Estazolam | 35 | suppressed |
| Sure Comfort | Syringe-Needle,insulin,0.5 Ml | 35 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | suppressed |
| Meloxicam | Meloxicam | 34 | 11 |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Anastrozole | Anastrozole | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 33 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 23 |
| Mometasone Furoate | Mometasone Furoate | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 27 | 27 |
| Trazodone Hcl | Trazodone Hcl | 27 | suppressed |
| Alprazolam | Alprazolam | 26 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 24 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 23 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 23 | 11 |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 23 | 13 |
| Fluconazole | Fluconazole | 22 | 20 |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Minoxidil | Minoxidil | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 16 |
| Amoxicillin | Amoxicillin | 19 | 17 |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | 11 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 17 | suppressed |
| Glyburide | Glyburide | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Novofine Plus | Pen Needle, Diabetic | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Insulin Glargine | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 14 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,030.01 · 35 records | Boehringer Ingelheim Pharmaceuticals, Inc. | CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, EVENITY, GARDASIL 9, JARDIANCE, Kerendia, LOKELMA, MOUNJARO, Ozempic, PROLIA, REPATHA, Rybelsus, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error